CytomX Therapeutics Inc. Common Stock (CTMX)
Stock · NASDAQ · Health Care
$2.28as of 10/16/2026
Price chart
Active signals
CTMX Signal Track Record
How signals performed across all stocks →What CTMX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -4.8% | 38% | September 14, 2026 |
| Bollinger Band Breakdown | 24 | -3.2% | 46% | September 15, 2026 |
| Bollinger Band Breakout | 20 | -5.9% | 30% | September 1, 2026 |
| 200-Day Moving Average TouchActive now | 9 | -5.1% | 22% | May 11, 2026 |
| Any 20-session window (baseline) | -4.2% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targ…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 69
- Website
- cytomx.com/
Fundamentals
- 1-day range
- $2.26$2.44
- Market cap
- $733.66M
- P/E (trailing)
- —
- P/E (forward)
- -4.85
- EPS (trailing)
- $-0.44
- Dividend yield
- —
- Beta
- 2.26
- Avg. volume
- 3.33M
How CytomX Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
CytomX Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CTMXCytomX Therapeutics Inc. Common Stock$2.28▼ 5.39%Market cap $733.66MP/E —$2.2$8.21
- RIGLRigel Pharmaceuticals Inc. Common Stock$45.97▼ 2.71%Market cap $732.62MP/E 2.76$24.95$52.24
- CYRXCryoPort Inc. Common Stock$16.84▼ 1.35%Market cap $741.42MP/E —$7.61$18.36
- OCSOculis Holding AG Ordinary shares$7.29▼ 1.49%Market cap $717.85MP/E —$7.11$34.48
- GYREGyre Therapeutics Inc. Common Stock$6.08▼ 5.00%Market cap $713.53MP/E —$5.44$9.42
- BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$2.82▼ 4.41%Market cap $703.34MP/E —$3.79$14.87
- ZVRAZevra Therapeutics Inc. Common Stock$9.94▼ 3.21%Market cap $702.29MP/E 10.81$8.01$15.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CTMX CytomX Therapeutics Inc. Common Stock | $733.66M | — | $2.28 | ▼ 5.39% | $2.2$8.21 |
| RIGL Rigel Pharmaceuticals Inc. Common Stock | $732.62M | 2.76 | $45.97 | ▼ 2.71% | $24.95$52.24 |
| CYRX CryoPort Inc. Common Stock | $741.42M | — | $16.84 | ▼ 1.35% | $7.61$18.36 |
| OCS Oculis Holding AG Ordinary shares | $717.85M | — | $7.29 | ▼ 1.49% | $7.11$34.48 |
| GYRE Gyre Therapeutics Inc. Common Stock | $713.53M | — | $6.08 | ▼ 5.00% | $5.44$9.42 |
| BBOT BridgeBio Oncology Therapeutics Inc. Common Stock | $703.34M | — | $2.82 | ▼ 4.41% | $3.79$14.87 |
| ZVRA Zevra Therapeutics Inc. Common Stock | $702.29M | 10.81 | $9.94 | ▼ 3.21% | $8.01$15.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Alejandra Carvajal · August 3, 2026 · Grant450.0K
- Alejandra Carvajal · August 3, 2026 · Grant100.0K
- Fuchs Charles S. · July 24, 2026 · Grant118.0K
- Su Zhen · June 17, 2026 · Grant59.0K
- Young Matthew P. · June 17, 2026 · Grant59.0K
- Mohindru Mani · June 17, 2026 · Grant59.0K
- Halley E. Gilbert · June 17, 2026 · Grant59.0K
- Ashworth Alan · June 17, 2026 · Grant59.0K
- Meyers James R · June 17, 2026 · Grant59.0K
- Jones Elaine V · June 17, 2026 · Grant59.0K
- Christopher Ogden · June 15, 2026 · Sale1.6K @ $3.05
Institutional Ownership
March 31, 2026
- Total shares held
- 195.36M
- Total value held
- $917.31M
- Institutional holders
- 174
- Unknown31.96M
- Unknown15.01M
- Unknown10.20M
- Unknown10.10M
- Unknown9.98M
- Unknown8.73M
- Unknown7.88M
- Unknown5.90M
- Unknown5.66M
- Unknown5.23M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
CTMX to Present at September Investor Conferences
CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.
CTMX to Present at September Investor Conferences. CytomX Therapeutics announced it will present at upcoming investor conferences in September, a routine corporate event where biotech firms typically discuss pipeline progress and business strategy with institutional investors and analysts. The company's shares have been trading in a notably wide range over the past year, between $1.90 and $8.21, reflecting the volatility common among smaller biotechnology companies working to advance their drug candidates through development. The September conference presentations could provide updated information on CytomX's ongoing programs and corporate priorities.